US Patent Issued to ADAMED PHARMA on Sept. 16 for "1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-Cpyrrole-2,3'-dione compounds as therapeutic agents activating TP53" (Polish Inventors)

ALEXANDRIA, Va., Sept. 17 -- United States Patent no. 12,415,811, issued on Sept. 16, was assigned to ADAMED PHARMA S.A. (Czosnow, Poland).

"1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-Cpyrrole-2,3'-dione compounds as therapeutic agents activating TP53" was invented by Marcin Feder (Warsaw, Poland), Maria Mazur (Warsaw, Poland), Iwona Kalinowska (Warsaw, Poland), Joanna Jaszczewska-Adamczak (Warsaw, Poland), Wojciech Lewandowski (Grojec, Poland), Jakub Witkowski (Warsaw, Poland), Sabina Jelen (Warsaw, Poland) and Katarzyna Wos-Latosi (Lomianki, Poland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to 1,2,3',5'-tetrahydro-2'H-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione...